Accurate Education - Acetyl-L-Carnitine (ALC) Impacts Pain Processing

Pain Processing:

How Acetyl-L-Carnitine (ALC) Impacts Pain Processing

See:

Acetyl-L-Carnitine (ALC)

How Nutraceuticals Impact Pain Processing

Pain Processing

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

See (On this Page):

Acetyl-L-Carnitine (ALC) : Pain Processing Effects vs. Direct Tissue-Modifying Effects

How Acetyl-L-Carnitine (ALC) Impacts Pain Processing

Acetyl-L-carnitine (ALC) exerts , from peripheral nociceptors through spinal cord processing to supraspinal modulation, while simultaneously addressing the four pathological processes central to the Pain Processing treatment paradigm: Systemic Inflammation, Neuroinflammation, Oxidative Stress and Mitochondrial Dysfunction.

The Levels of Pain Processing can be organized as follows:

Level 1: Peripheral Nociception (Pain Receptor Transduction): Activation and Sensitization
Level 2: Primary Afferent Transmission to Spinal Cord
Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)
Level 4: Ascending Spinal Pathways and Supraspinal Processing
Level 5: Thalamic and Cortical Processing and Pain Perception
Level 6: Descending Pain Modulation

Level 1: Peripheral Nociception (Pain Receptor Transduction) Activation and Sensitization

At the peripheral level, ALC promotes nerve fiber regeneration and reduces sensory neuronal loss.

It increases nerve conduction velocity and supports the structural integrity of primary afferent neurons through neurotrophic effects mediated by nerve growth factor (NGF).
ALC also upregulates mGlu2 receptors directly in dorsal root ganglia (DRG) neurons—the cell bodies of primary afferents—where these receptors function to inhibit nociceptor excitability, thereby reducing peripheral sensitization
By reducing peripheral sensitization, ALC decreases the aberrant signaling that initiates the pain cascade.
Additionally, ALC’s antioxidant properties protect peripheral nerve terminals from oxidative damage that contributes to neuropathic pain states.

Nerve Growth Factor (NGF) Modulation:

ALC amplifies nerve growth factor responsiveness, an effect that enhances overall neurite growth and supports peripheral nerve function.[4] In cisplatin-treated animals, ALC cotreatment was correlated with modulation of plasma levels of NGF, and experiments indicated that ALC, in the presence of NGF, positively modulated NGFI-A expression—a gene relevant in the rescue from tissue-specific toxicity.

Peripheral Nerve Protection and Regeneration:

ALC facilitates nerve regeneration and damage repair after primary trauma. Its positive effects on metabolism promote the synthesis, fluidity, and functionality of neuronal membranes, increase protein synthesis, and improve the axonal transport of neurofilament proteins and tubulin. A morphological study demonstrated that ALC significantly increased the number of regenerating nerve fibers (24,460 vs. 17,217 in controls, P<0.01), improved myelin thickness, and enhanced target organ reinnervation.

Reduction of Peripheral Sensitization:

ALC can improve the function of peripheral nerves by increasing nerve conduction velocity, reducing sensory neuronal loss, and promoting nerve regeneration. These effects help maintain normal peripheral nerve function and reduce aberrant signaling associated with nerve injury.

Level 2: Primary Afferent Transmission to Spinal Cord

ALC supports the metabolic health of primary afferent nerve fibers by facilitating mitochondrial fatty acid β-oxidation and ATP production. This is particularly relevant in conditions where mitochondrial dysfunction underlies neuropathy (diabetic neuropathy, HIV-associated neuropathy, chemotherapy-induced neuropathy). ALC also provides acetyl groups for myelin synthesis and membrane repair, supporting the structural integrity of both myelinated Aδ and unmyelinated C fibers. The anti-apoptotic effects of ALC—mediated through nicotinic receptor activation and inhibition of mitochondrial permeability transition—protect sensory neurons from degeneration.

DRG Neuron mGlu2 Receptor Upregulation:

ALC’s most distinctive mechanism involves epigenetic upregulation of mGlu2 receptors in dorsal root ganglia neurons. LAC-induced upregulation of mGlu2 expression in DRG cultures involves transcriptional activation mediated by NF-κB. A single application of LAC (250 μM) to DRG cultures induced a transient increase in mGlu2 mRNA, which was observable after 1 hour. LAC treatment had no effect on mGlu3 mRNA expression, demonstrating selectivity for mGlu2.

LAC induced an increase in the acetylation of p65/RelA, a process that enhances the transcriptional activity of p65/RelA. Importantly, carnitine (without the acetyl group), which has no effect on pain thresholds, had no effect on p65/RelA acetylation and did not enhance mGlu2 expression—confirming the critical role of the acetyl moiety.

Histone Acetylation in DRG:

The epigenetic mechanism extends to histone modification. ALC treatment was associated with increased levels of acetylated histone H3 bound to the Grm2 gene promoter in the dorsal root ganglia. This epigenetic modification persisted for two weeks after drug withdrawal, explaining the long-lasting analgesic effects.

Primary Afferent Excitability Modulation:

By upregulating mGlu2 receptors on primary afferent terminals, ALC creates an inhibitory feedback mechanism. Activation of presynaptic mGlu2 receptors reduces glutamate release from nociceptive afferents, thereby dampening excitatory transmission in pain pathways.

Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)

This is arguably ALC’s most critical site of action. ALC epigenetically upregulates mGlu2 receptor expression in the dorsal horn through acetylation of the p65/RelA transcription factor, which enhances transcription of the GRM2 gene encoding mGlu2 receptors. mGlu2 receptors are located presynaptically on glutamatergic terminals in laminae II-IV of the dorsal horn, where they function as autoreceptors to inhibit glutamate release. This reduces excitatory neurotransmission at the first central synapse and prevents the development of central sensitization.

The epigenetic nature of this mechanism produces uniquely long-lasting analgesia. In mouse models, ALC-induced analgesia persisted for 37 days after drug withdrawal, compared to only 7-15 days for pregabalin or amitriptyline. This effect was associated with sustained increases in mGlu2/3 receptor protein levels and increased acetylated histone H3 bound to the Grm2 gene promoter in DRG neurons.

ALC also counteracts spinal glial activation. In models of visceral pain, ALC reduced spinal astrocyte activation (GFAP expression), which contributes to central sensitization through release of pro-inflammatory mediators and glutamate.

Spinal mGlu2/3 Receptor Upregulation:

ALC treatment enhanced mGlu2/3 receptor protein levels in the dorsal region of the spinal cord. In both CCI- and sham-operated rats, a 24-day treatment with LAC increased the expression of mGlu2 and mGlu3 receptors in the lumbar segment of the spinal cord, without changing the expression of mGlu1a or mGlu5 receptors.

Immunohistochemical analysis showed that LAC treatment enhanced mGlu2/3 immunoreactivity in the inner part of lamina II and in laminae III and IV of the spinal cord—regions critical for nociceptive processing.

Prevention of Central Sensitization:

ALC induces mGlu2 expression at nerve terminals, thus giving rise to analgesia and preventing spinal sensitization. This mechanism is particularly relevant for chronic pain states characterized by nociplastic changes that increase the sensitivity of the nervous system to pain.

Long-Lasting Spinal Effects:

The epigenetic nature of ALC’s mechanism produces uniquely persistent effects. A seven-day treatment with L-acetylcarnitine (100 mg/kg, once a day, i.p.) produced an antiallodynic effect in the CFA mouse model of chronic inflammatory pain. L-Acetylcarnitine-induced analgesia persisted for at least 14 days after drug withdrawal. In contrast, the analgesic effect of pregabalin, amitriptyline, ceftriaxone, and N-acetylcysteine disappeared seven days after drug withdrawal.

In mice subjected to chronic constriction injury of the sciatic nerve, only in mice treated with L-acetylcarnitine did analgesia persist 37 days after drug withdrawal. This effect was associated with an increase in mGlu2/3 receptor protein levels in the dorsal horns of the spinal cord.

Glial Modulation:

ALC counteracts enteric glia and spinal astrocyte activation. In a model of visceral pain associated with colitis, ALC counteracted enteric glia and spinal astrocyte activation resulting from colitis, as analyzed by immunofluorescence. The preventive protocol effectively protected enteric neurons from the inflammatory insult.

PKCγ and MAPK Activation:

Interestingly, ALC activates certain signaling pathways associated with both pain and neuroregeneration. In CCI rats, ALC treatment stimulated expression of activated PKCγ, ERK 1,2, p38, SAP/JNK, and c-Jun proteins in the ipsilateral side of the spinal cord. At the transcriptional level, ALC had a stimulatory effect on both c-Jun and c-Fos early genes. These findings represent the complex balance between pain modulation and neuroregeneration.

Level 4: Ascending Spinal Pathways and Supraspinal Processing

While direct evidence for ALC effects on ascending tract neurons is limited, the reduction in dorsal horn excitability logically decreases the magnitude of nociceptive signals transmitted via spinothalamic and spinoparabrachial pathways. ALC’s protection against excitotoxicity—demonstrated through inhibition of NMDA-mediated neuronal death—may preserve the integrity of projection neurons.

Cortical mGlu2 Receptor Upregulation:

ALC’s epigenetic effects extend to supraspinal structures. An increased mGlu2/3 receptor expression was observed in the cerebral cortex but not in the hippocampus or cerebellum of LAC-treated animals. Reverse transcription-PCR combined with Northern blot analysis showed that repeated LAC injections selectively induced mGlu2 mRNA in the dorsal horns and cerebral cortex.

Hippocampal and Prefrontal Cortex Effects:

ALC increased levels of acetylated H3K27 bound to the Grm2 promoter and also increased acetylation of NF-κB-p65 subunit, thereby enhancing the transcription of Grm2 gene encoding for the mGlu2 receptor in hippocampus and prefrontal cortex.

Neurotransmitter Modulation:

ALC modulates brain neurotransmitters such as acetylcholine, serotonin, and dopamine. ALC provides acetyl groups for acetylcholine synthesis and exerts a cholinergic effect, which may influence pain processing at supraspinal levels.

Level 5: Thalamic and Cortical Processing and Pain Perception

ALC crosses the blood-brain barrier and exerts effects on supraspinal pain processing centers. It modulates brain neurotransmitters critical to pain perception, including:

Acetylcholine: ALC provides acetyl groups for acetylcholine synthesis, enhancing cholinergic neurotransmission in forebrain regions involved in pain modulation and cognition
Serotonin: Chronic ALC supplementation increases serotonin content in the cortex
Norepinephrine: ALC increases noradrenaline levels in the hippocampal formation
Dopamine: ALC modulates dopaminergic transmission and upregulates D1 receptors

ALC also increases mGlu2 receptor expression in the cerebral cortex (but not hippocampus or cerebellum), suggesting region-specific effects on cortical pain processing.Functional imaging studies show that ALC increases cerebral metabolic rates for glucose in prefrontal, somatosensory, and cingulate cortices—regions implicated in both sensory-discriminative and affective-motivational aspects of pain.

Neuroprotection and Cognitive Function:

ALC has demonstrated cytoprotective, antioxidant, and antiapoptotic effects in the nervous system. It has been proposed for the treatment of various neurological and psychiatric diseases, including mood disorders and depression, dementias, Alzheimer’s disease, and Parkinson’s disease, because synaptic energy states and mitochondrial dysfunction are core factors in their pathogenesis.

Synaptic Plasticity:

ALC plays neuromodulatory effects on both synaptic morphology and synaptic transmission. These effects are likely due to modulation of gene expression on several targets in the central nervous system.

Proneurogenic Effects:

ALC is a proneurogenic molecule, whose effect on neuronal differentiation of adult hippocampal neural progenitors is independent of its neuroprotective activity. Chronic ALC treatment significantly increased adult-born neurons in hippocampi of stressed and unstressed mice, which may contribute to improved cortical pain processing.

ALC’s enhancement of serotonergic and noradrenergic neurotransmission directly supports descending inhibitory pathways originating from the periaqueductal gray (PAG), rostral ventromedial medulla (RVM), and locus coeruleus. These monoaminergic systems are the same targets of SNRIs and TCAs used for neuropathic pain. ALC’s cholinergic effects may also enhance descending modulation, as muscarinic receptor activation in the forebrain contributes to antinociception.

Level 6: Descending Pain Modulation

Acetyl-L-carnitine (ALC) impacts descending pain modulation primarily through epigenetic upregulation of metabotropic glutamate 2 (mGlu2) receptors in the spinal cord and dorsal root ganglia, which enhances inhibitory neurotransmission and prevents spinal sensitization.

The mechanism involves ALC acting as a donor of acetyl groups to transcription factors in the NF-κB family, specifically acetylating NF-κB p65/RelA, which enhances transcription of the GRM2 gene encoding mGlu2 receptors.This epigenetic modification leads to increased mGlu2 receptor expression at nerve terminals in the dorsal horns of the spinal cord (particularly in the inner part of lamina II and in laminae III and IV) and in dorsal root ganglia. The upregulation of mGlu2 receptors is selective—ALC increases mGlu2 but not mGlu3, mGlu1a, or mGlu5 receptor expression.

The functional consequence of enhanced mGlu2 receptor expression is analgesia through presynaptic inhibition of glutamate release, which prevents spinal sensitization and reduces pain transmission. This mechanism has been confirmed through antagonist studies: the mGlu2/3 receptor antagonist LY341495 largely abolishes ALC-induced analgesia, demonstrating the causal relationship between mGlu2 upregulation and pain relief.

A distinctive feature of ALC’s effect on descending pain modulation is its long-lasting analgesic action that persists well beyond treatment cessation—analgesia can continue for 14-37 days after drug withdrawal in animal models, far outlasting other analgesics like pregabalin or amitriptyline. This durability reflects the epigenetic nature of the mechanism, with sustained increases in acetylated histone H3 bound to the Grm2 gene promoter.

References

Acetyl-L-Carnitine in Chronic Pain: A Narrative Review. Sarzi-Puttini P, Giorgi V, Di Lascio S, Fornasari D. Pharmacological Research. 2021;173:105874. doi:10.1016/j.phrs.2021.105874.
Analgesia Induced by the Epigenetic Drug, L-Acetylcarnitine, Outlasts the End of Treatment in Mouse Models of Chronic Inflammatory and Neuropathic Pain. Notartomaso S, Mascio G, Bernabucci M, et al. Molecular Pain. 2017;13:1744806917697009. doi:10.1177/1744806917697009.
L-Acetylcarnitine Induces Analgesia by Selectively Up-Regulating mGlu2 Metabotropic Glutamate Receptors. Chiechio S, Caricasole A, Barletta E, et al. Molecular Pharmacology. 2002;61(5):989-96. doi:10.1124/mol.61.5.989.
Acetyl-L-Carnitine: From a Biological Curiosity to a Drug for the Peripheral Nervous System and Beyond. Onofrj M, Ciccocioppo F, Varanese S, et al. Expert Review of Neurotherapeutics. 2013;13(8):925-36. doi:10.1586/14737175.2013.814930.
Acetyl-L-Carnitine in Neuropathic Pain: Experimental Data. Chiechio S, Copani A, Gereau RW, Nicoletti F. CNS Drugs. 2007;21 Suppl 1:31-8; discussion 45-6. doi:10.2165/00023210-200721001-00005.
L-Acetylcarnitine Causes Analgesia in Mice Modeling Fabry Disease by Up-Regulating Type-2 Metabotropic Glutamate Receptors. Formaggio F, Rimondini R, Delprete C, et al. Molecular Pain. 2022 Jan-Dec;18:17448069221087033. doi:10.1177/17448069221087033.

Understanding Systemic Inflammation, Neuroinflammation, Oxidative Stress and Mitochondrial Dysfunction

Systemic Inflammation, Neuroinlammation, Oxidative Stress and Mitochondrial Dysfunction are 4 pathological processes/conditions that contribute to chronic pain by creating a cycle of tissue damage, immune cell activation, and pain amplification. By disrupting normal cellular physiology, these conditions also contribute to the development and progression of chronic diseases, including diabetes, heart disease, stroke, chronic kidney and liver disease, rheumatoid arthritis, cancer and Alzheimer’s.

Systemic inflammation (SI) is a widespread inflammatory response throughout the body, triggered by infection, injury, stress and other conditions. It involves activation of the immune system with the release of pro-inflammatory compounds that contribute to chronic pain and lead to other health issues. Symptoms of SI include increased pain, fatigue, cognitive problems, depression, decreased motivation for physical activity and, in severe cases, organ dysfunction. While inflammation is a natural part of the healing process, chronic or excessive SI contributes to the development of heart disease, diabetes, and autoimmune disorders like rheumatoid arthritis.
Neuroinflammation (NI), a component of systemic inflammation, is inflammation within the central nervous system (brain and spinal cord). SI releases inflammatory compounds that cross into the brain and spinal cord that activate immune cells causing NI and contributes to the progression of acute to chronic pain. NI is characterized by activation of immune cells (glial cells and astrocytes) in the nervous system that release inflammatory chemicals like cytokines, proteases, and free radicals such as reactive oxygen (ROS), and nitrogen species (RNS). When these immune cells remain activated, neuroinflammation persists and drives chronic pain.
Oxidative stress (OS) is an imbalance of excessive “oxidants” (“oxidizing” or chemically active agents (including ROS and NOS) obtained from the diet or produced by the body coupled with insufficient “antioxidants,” the compounds that neutralize oxidants. Excessive oxidants damage nerve cells and other tissues causing and maintaining pain. Antioxidants are manufactured by the body, but sufficient dietary intake of antioxidants is critical for good health. OS and chronic SI co-exist and feed each other, damaging tissues in a vicious cycle that further worsens pain.
Mitochondrial Dysfunction (MD). Mitochondria are organelles found in cells that function as the “power stations” of cells in that they process food into energy. In addition to providing energy, they play a major role in maintaining antioxidants to combat OS and SI. Because mitochondria impact the metabolism of all cells, they play a huge role in general health. Impairment of mitochondrial function (dysfunction) contributes to many conditions including chronic pain, obesity, migraines, fibromyalgia, diabetes, heart disease and neurodegenerative diseases like Alzheimers. In MD, energy production goes down and fatigue develops along with impaired physical functioning, even if more calories are ingested. MD is the hallmark of conditions such as obesity and fibromyalgia. Mitochondrial dysfunction leads to the metabolic impairment that is found in many chronic diseases including depression, bipolar disorders and premature aging.

Integration of Pain Processing with the 4 Pathological Processes

1. Systemic Inflammation:

ALC exerts anti-inflammatory effects through multiple mechanisms:

TLR4/NF-κB Pathway Suppression:

ALC confers neuroprotection against LPS-induced neuroinflammation by suppression of TLR4/NF-κB pathway. Intraperitoneal administration of ALC contributed to neuroprotection by suppressing TLR4/NF-κB pathway activation, restoring activity of autophagy, and inhibiting oxidative stress.

Pro-inflammatory Cytokine Reduction:

ALC reduced the expressions of inflammation factors TNF-α, IL-1β, iNOS, and CRP in serum, aortic, and heart tissues. ALC also reduced the concentration of angiotensin II (AngII) in these tissues.]

Paradoxical NF-κB Activation for Analgesia:

Importantly, while ALC suppresses inflammatory NF-κB signaling in the context of systemic inflammation, it enhances NF-κB p65 acetylation in DRG neurons to upregulate mGlu2 receptors. This context-dependent effect demonstrates the complexity of ALC’s mechanism—acetylation of p65 enhances its transcriptional activity for specific genes (like GRM2) while the overall anti-inflammatory effect reduces pathological NF-κB activation.

2. Neuroinflammation:

ALC comprehensively addresses neuroinflammation:

Microglial and Astrocyte Modulation:

ALC counteracts glial activation in both the enteric and central nervous systems. In colitis-induced visceral pain, ALC counteracted enteric glia and spinal astrocyte activation, as analyzed by immunofluorescence.

Neuroinflammatory Pathway Inhibition:

ALC attenuated LPS-induced neuroinflammation by targeting TLR4/NF-κB pathway, autophagy, and oxidative stress. LPS injection resulted in initiation of neuroinflammation by activation of TLR4/NF-κB and suppression of autophagic markers; ALC reversed these changes.

Benefits in Neuroinflammatory Diseases:

Dietary supplementation of ALC has shown health benefits in neuroinflammation, which is a common denominator in a host of neurodegenerative diseases.

3. Oxidative Stress:

ALC addresses oxidative stress through multiple mechanisms:

Antioxidant Properties:

ALC has antioxidant properties and protects from oxidative stress. It has demonstrated cytoprotective, antioxidant, and antiapoptotic effects in the nervous system.

Antioxidant Enzyme Enhancement:

ALC enhanced the activities of antioxidant enzymes. In ischemic stroke patients, ALC treatment resulted in a significant increase in serum levels of antioxidant biomarkers, including glutathione peroxidase (GPx), superoxide dismutase (SOD), and total antioxidant capacity (TAC).

Reduction of Oxidative Damage:

ALC enhanced SOD and GSH-Px activities and decreased MDA activity, indicating reduced lipid peroxidation.

Mitochondrial Protection from Oxidative Damage:

ALC protects mitochondria from oxidative damage and inhibits apoptosis caused by mitochondrial damage.

4. Mitochondrial Dysfunction:

ALC plays a central role in mitochondrial function:

Fatty Acid Transport and β-Oxidation:

ALC plays an essential role in intermediary metabolism, acting as a donor of acetyl groups and facilitating the transfer of fatty acids from cytosol to mitochondria during beta-oxidation. The amino acid acetyl-L-carnitine plays a role in the transfer of long-chain fatty acids into mitochondria for β-oxidation.

Energy Metabolism Optimization:

ALC optimizes the balance of energy processes. Carnitine acetylation enables the function of CoA and facilitates elimination of oxidative products.

Acetyl-CoA Supply:

ALC can provide an acetyl moiety that can be oxidized for energy, used as a precursor for acetylcholine, or incorporated into glutamate, glutamine and GABA, or into lipids for myelination and cell growth. In glucose-limited cells, exogenous LAC contributed more robustly to intracellular acetyl-CoA pools than did β-hydroxybutyrate.

Mitochondrial Bioenergetics:

ALC exhibits positive effects on mitochondrial metabolism and shows promise in the treatment of aging and neurodegenerative pathologies by slowing the progression of mental deterioration.

Summary Table

ALC’s effects at each pain pathway level are mechanistically linked to its actions on the four target pathological conditions:

Pathological Process	ALC Mechanism	Pain Pathway Impact
Systemic Inflammation	Reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6); balances pro/anti-inflammatory cytokine ratio	Decreases peripheral sensitization; reduces inflammatory mediator-induced nociceptor activation
Neuroinflammation	Suppresses TLR4/NF-κB pathway; attenuates microglial activation; reduces astrocyte reactivity (GFAP); increases BDNF	Prevents spinal and supraspinal glial-mediated central sensitization; protects synaptic function
Oxidative Stress	Direct ROS scavenging; increases glutathione (GSH); upregulates heat shock proteins (HSPs); reduces protein carbonylation and lipid peroxidation	Protects peripheral nerves, DRG neurons, and CNS neurons from oxidative damage; preserves mitochondrial membrane integrity
Mitochondrial Dysfunction	Facilitates fatty acid transport into mitochondria for β-oxidation; serves as acetyl group donor for Krebs cycle; promotes mitochondrial biogenesis via ERK-Nrf2-PGC-1α pathway; inhibits mitochondrial permeability transition	Restores neuronal energy metabolism; prevents apoptosis; supports nerve regeneration and synaptic function

Summary: ALC as a Multi-Level Pain Modulator

ALC is unique among nutraceuticals in that it exerts direct analgesic effects through epigenetic upregulation of mGlu2 receptors while simultaneously addressing all four pathological processes that amplify pain processing. Its effects span

References

Mechanisms of Chronic Pain. Markenson JA. The American Journal of Medicine. 1996;101(1A):6S-18S. doi:10.1016/s0002-9343(96)00133-7.
Molecular Anatomy of Synaptic and Extrasynaptic Neurotransmission Between Nociceptive Primary Afferents and Spinal Dorsal Horn Neurons. Antal M. International Journal of Molecular Sciences. 2025;26(5):2356. doi:10.3390/ijms26052356.
Spinal Cord Mechanisms of Pain. D’Mello R, Dickenson AH. British Journal of Anaesthesia. 2008;101(1):8-16. doi:10.1093/bja/aen088.
Excitatory and Inhibitory Neurons of the Spinal Cord Superficial Dorsal Horn Diverge in Their Somatosensory Responses and Plasticity . Sullivan SJ, Sdrulla AD. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience. 2022;42(10):1958-1973. doi:10.1523/JNEUROSCI.1860-21.2021.
Network Model of Nociceptive Processing in the Superficial Spinal Dorsal Horn Reveals Mechanisms of Hyperalgesia, Allodynia, and Spinal Cord Stimulation. Gilbert JE, Zhang T, Esteller R, Grill WM. Journal of Neurophysiology. 2023;130(5):1103-1117. doi:10.1152/jn.00186.2023.
Acute and Chronic Pain Processing in the Thalamocortical System of Humans and Animal Models. Groh A, Krieger P, Mease RA, Henderson L. Neuroscience. 2018;387:58-71. doi:10.1016/j.neuroscience.2017.09.042.
Convergence of Sensory and Limbic Noxious Input Into the Anterior Insula and the Emergence of Pain From Nociception. Bastuji H, Frot M, Perchet C, Hagiwara K, Garcia-Larrea L. Scientific Reports. 2018;8(1):13360. doi:10.1038/s41598-018-31781-z.
Cortical Modulation of Nociception. Gamal-Eltrabily M, Martínez-Lorenzana G, González-Hernández A, Condés-Lara M. Neuroscience. 2021;458:256-270. doi:10.1016/j.neuroscience.2021.01.001.
The ‘In’s and Out’s’ of Descending Pain Modulation From the Rostral Ventromedial Medulla. De Preter CC, Heinricher MM. Trends in Neurosciences. 2024;47(6):447-460. doi:10.1016/j.tins.2024.04.006.
The Plasticity of Descending Controls in Pain: Translational Probing. Bannister K, Dickenson AH. The Journal of Physiology. 2017;595(13):4159-4166. doi:10.1113/JP274165.
Inputs to the Locus Coeruleus From the Periaqueductal Gray and Rostroventral Medulla Shape Opioid-Mediated Descending Pain Modulation. Lubejko ST, Livrizzi G, Buczynski SA, et al. Science Advances. 2024;10(17):eadj9581. doi:10.1126/sciadv.adj9581.
Brainstem Mechanisms of Pain Modulation: A Within-Subjects 7T fMRI Study of Placebo Analgesic and Nocebo Hyperalgesic Responses. Crawford LS, Mills EP, Hanson T, et al. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience. 2021;41(47):9794-9806. doi:10.1523/JNEUROSCI.0806-21.2021.
Nonnarcotic Methods of Pain Management. Finnerup NB. The New England Journal of Medicine. 2019;380(25):2440-2448. doi:10.1056/NEJMra1807061.
Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. Guo L, Pan Q, Cheng Z, et al. Diabetes. 2024;73(5):797-805. doi:10.2337/db23-0377.
Potential Therapeutic Role of Carnitine and Acetylcarnitine in Neurological Disorders. Maldonado C, Vázquez M, Fagiolino P. Current Pharmaceutical Design. 2020;26(12):1277-1285. doi:10.2174/1381612826666200212114038.
The Neurobiology of Acetyl-L-Carnitine. Traina G. Frontiers in Bioscience (Landmark Edition). 2016;21(7):1314-29. doi:10.2741/4459.
Effects of Acetyl-L-Carnitine in Diabetic Neuropathy and Other Geriatric Disorders. Sergi G, Pizzato S, Piovesan F, et al. Aging Clinical and Experimental Research. 2018;30(2):133-138. doi:10.1007/s40520-017-0770-3.
Carnitine Derivatives: Clinical Usefulness. Malaguarnera M. Current Opinion in Gastroenterology. 2012;28(2):166-76. doi:10.1097/MOG.0b013e3283505a3b.
Tolerability and Efficacy of L-Acetylcarnitine in Patients With Peripheral Neuropathies: A Short-Term, Open Multicentre Study. Grandis DD. Clinical Drug Investigation. 1998;15(2):73-9. doi:10.2165/00044011-199815020-00001.
Treatment of Alzheimer’s Disease. Mayeux R, Sano M. The New England Journal of Medicine. 1999;341(22):1670-9. doi:10.1056/NEJM199911253412207.
Acetyl-L-Carnitine for the Treatment of Diabetic Peripheral Neuropathy. Rolim LC, da Silva EM, Flumignan RL, Abreu MM, Dib SA. The Cochrane Database of Systematic Reviews. 2019;6:CD011265. doi:10.1002/14651858.CD011265.pub2.
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Loprinzi CL, Lacchetti C, Bleeker J, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399.
Intestinal Microbiota in Cardiovascular Health and Disease: JACC State-of-the-Art Review. Tang WHW, Bäckhed F, Landmesser U, Hazen SL. Journal of the American College of Cardiology. 2019;73(16):2089-2105. doi:10.1016/j.jacc.2019.03.024.
Intestinal Microbiota Metabolism of L-Carnitine, a Nutrient in Red Meat, Promotes Atherosclerosis. Koeth RA, Wang Z, Levison BS, et al. Nature Medicine. 2013;19(5):576-85. doi:10.1038/nm.3145.

—

Clinical Evidence Supporting Pain Pathway Effects

Diabetic Peripheral Neuropathy:

A Cochrane systematic review of ALC for diabetic peripheral neuropathy included four studies with 907 participants. ALC reduced pain more than placebo, measured on a 0- to 100-mm VAS (MD -9.16, 95% CI -16.76 to -1.57; P = 0.02). Importantly, at doses greater than 1500 mg/day, ALC reduced pain more than placebo (MD -14.93, 95% CI -19.16 to -10.70; P < 0.00001), while at doses of 1500 mg/day or less, the effect was not different from placebo.

A phase 3 randomized clinical trial in China (n=458) found that ALC (1500 mg/day) produced a significantly greater reduction in modified Toronto clinical neuropathy score compared with placebo (-6.9 ± 5.3 vs. -4.7 ± 5.2 points; P < 0.001), representing a 0.65-fold improvement in treatment efficacy. The remaining 10 components of mTCNS showed significant improvement in the ALC group compared with the placebo group (P < 0.05 for all).

Two 52-week randomized placebo-controlled trials (n=1,257) demonstrated that ALC treatment showed significant improvements in sural nerve fiber numbers and regenerating nerve fiber clusters. Vibration perception improved in both studies, and pain as the most bothersome symptom showed significant improvement in the combined cohort taking 1000 mg ALC t.i.d.

Peripheral Neuropathic Pain (Meta-Analysis):

A systematic review and meta-analysis of randomized controlled trials (n=523) found that compared with placebo, ALC significantly reduced VAS scores of peripheral neuropathic pain patients (MD of VAS, 1.20; 95% CI, 0.68-1.72, P < 0.00001). In subgroup analysis, ALC appeared more effective in diabetic PNP patients than non-diabetic PNP patients (diabetic subgroup: MD, 1.47; 95% CI, 1.06-1.87, P < 0.00001; non-diabetic subgroup: MD, 0.71; 95% CI, -0.01-1.43, P = 0.05).

Large Open-Label Study:

A multicentre study of 1,097 patients with peripheral neuropathies of various aetiologies evaluated ALC administered intramuscularly (1000 mg/day for 10 days) then orally (2000 mg/day for 20 days). Neurological examination revealed that a significant percentage of patients with altered indices at baseline had normal indices by the end of the treatment period. Disease was rated as improved by 83.1% of investigators and 84.2% of patients. In patients with reduced conduction velocities, significant increments were recorded for motor and sensory nerves.

Combination Therapy Evidence:

A 12-month prospective, double-blind, placebo-controlled study evaluated the combination of superoxide dismutase, alpha-lipoic acid, acetyl-L-carnitine, and vitamin B12 in diabetic neuropathy (n=85). At follow-up, the active group showed significant improvements in vibration perception threshold, Michigan Neuropathy Screening Instrument scores, quality of life, pain, and sural nerve conduction velocity and amplitude (P < 0.001 to P = 0.031 for various parameters).

Chemotherapy-Induced Peripheral Neuropathy (Negative Evidence):

Importantly, ALC has shown negative results for prevention of chemotherapy-induced peripheral neuropathy. The ASCO Guideline Update notes that in a trial of patients receiving paclitaxel, neuropathy was actually worse in patients who received ALC. In a long-term follow-up analysis, 24 weeks of ALC therapy resulted in statistically significantly worse CIPN (P = 0.01) over 2 years, as measured by the FACT-Ntx Questionnaire.

Comparison with Other Nutraceuticals

Feature	Acetyl-L-Carnitine	Alpha-Lipoic Acid	CoQ10	Nicotinamide Riboside
Primary mechanism	Epigenetic mGlu2 upregulation via p65 acetylation	Direct ROS scavenging; GSH regeneration	ETC electron carrier; membrane antioxidant	NAD+ precursor; SIRT activation
Mitochondrial role	Fatty acid transport for β-oxidation; acetyl-CoA supply	↑Complex I-IV activity; PDH/α-KGDH cofactor	Direct ETC component; ↑OXPHOS efficiency	NAD+ replenishment; SIRT1/3 activation
Epigenetic effects	NF-κB p65 acetylation; histone H3 acetylation at Grm2 promoter	Limited direct epigenetic effects	Indirect via oxidative stress reduction	SIRT-mediated histone deacetylation
Duration of effect	Persists 14-37 days after drug withdrawal	Effects diminish after discontinuation	Effects diminish after discontinuation	Effects diminish after discontinuation
Nerve regeneration	Direct neurotrophic effects; ↑nerve fiber numbers	Neuroprotective; limited regenerative data	Indirect via bioenergetic support	Indirect via NAD+-dependent repair
Clinical pain evidence	Strong: Multiple RCTs positive for diabetic neuropathy at doses >1500 mg/day	Strong: Multiple RCTs positive for diabetic neuropathy	Moderate: Positive in fibromyalgia, migraine	Limited: Emerging preclinical evidence
Optimal dosing	1500-3000 mg/day in divided doses	600-1800 mg/day	100-300 mg/day	250-1000 mg/day
Safety profile	Excellent; mild GI effects; no severe AEs	Excellent; rare GI effects	Excellent; rare mild GI effects	Excellent; well-tolerated

—

Unique Mechanistic Contributions of ALC

ALC offers several unique mechanisms not shared by other nutraceuticals in your paradigm:

1. Epigenetic Analgesia via mGlu2 Upregulation:

ALC’s most distinctive mechanism is its epigenetic induction of mGlu2 receptor expression through acetylation of NF-κB p65/RelA. This mechanism is unique among your selected nutraceuticals and produces analgesia that persists long after drug withdrawal—a property not seen with conventional analgesics or other nutraceuticals.

2. Nerve Regeneration and Neurotrophic Effects:

ALC is the only nutraceutical in your paradigm with demonstrated ability to increase regenerating nerve fiber clusters in human clinical trials. This neurotrophic effect addresses the structural damage underlying neuropathic pain, not just symptomatic relief.

3. Acetyl Group Donation:

ALC’s role as an acetyl group donor supports multiple cellular processes including acetylcholine synthesis, histone acetylation, and protein acetylation. This broad acetylation capacity distinguishes it from other mitochondrial-targeted nutraceuticals.

4. Long-Lasting Effects:

The epigenetic nature of ALC’s mechanism produces uniquely persistent analgesic effects. In preclinical models, ALC-induced analgesia persisted for 14-37 days after drug withdrawal, while the analgesic effects of pregabalin, amitriptyline, ceftriaxone, and N-acetylcysteine disappeared within 7 days.

—

Synergistic Potential with Other Nutraceuticals

ALC demonstrates significant potential for synergy with other agents in your paradigm:

With CoQ10:

ALC and CoQ10 address mitochondrial dysfunction through complementary mechanisms—ALC facilitates fatty acid transport for β-oxidation and provides acetyl-CoA, while CoQ10 serves as the electron carrier in the ETC. This combination may provide comprehensive mitochondrial support addressing both substrate supply and electron transport efficiency.

With Nicotinamide Riboside:

ALC’s acetyl group donation complements NR’s NAD+ replenishment. Both agents support sirtuin function—ALC through acetyl-CoA supply and NR through NAD+ substrate. This combination may provide enhanced epigenetic regulation through coordinated acetylation and deacetylation pathways.

With Alpha-Lipoic Acid:

Both ALC and ALA have demonstrated efficacy in diabetic neuropathy through distinct mechanisms. The combination of superoxide dismutase, alpha-lipoic acid, acetyl-L-carnitine, and vitamin B12 showed synergistic improvements in multiple neuropathy parameters in a 12-month clinical trial.[6]

With NAC:

Both ALC and NAC modulate glutamatergic neurotransmission but through different mechanisms—ALC upregulates mGlu2 receptors epigenetically while NAC activates mGlu2 receptors through system xc-. This combination may provide complementary glutamatergic modulation with both acute and long-term effects.

—

Summary

Acetyl-L-carnitine occupies a unique position in the nutraceutical paradigm for pain management through its distinctive epigenetic mechanism—acetylation of NF-κB p65/RelA leading to long-term upregulation of mGlu2 receptors in dorsal root ganglia, spinal cord, and cerebral cortex. This mechanism produces analgesia that persists for weeks after drug withdrawal, distinguishing ALC from all other agents in the paradigm.

ALC comprehensively addresses all four identified pathological processes:

Systemic inflammation (TLR4/NF-κB suppression, cytokine reduction),
Neuroinflammation (glial modulation),
Oxidative stress (antioxidant and antiapoptotic effects), and
Mitochondrial Dysfunction (fatty acid transport, acetyl-CoA supply, energy metabolism optimization).

Its unique neurotrophic effects, including demonstrated ability to increase regenerating nerve fiber clusters in human trials, address the structural basis of neuropathic pain.

Clinical evidence from multiple randomized controlled trials supports ALC’s efficacy in diabetic peripheral neuropathy, particularly at doses >1500 mg/day. The excellent safety profile with no severe adverse events supports its consideration as part of a comprehensive nutraceutical approach to pain processing. However, the negative results in chemotherapy-induced peripheral neuropathy suggest that ALC’s benefits may be condition-specific.

—

References

Oral Herbal Therapies for Treating Osteoarthritis. Cameron M, Chrubasik S. The Cochrane Database of Systematic Reviews. 2014;(5):CD002947. doi:10.1002/14651858.CD002947.pub2.
Comparative Effectiveness of Nutritional Supplements in the Treatment of Knee Osteoarthritis: A Network Meta-Analysis. Zhang Y, Gui Y, Adams R, et al. Nutrients. 2025;17(15):2547. doi:10.3390/nu17152547.
Boswellia Serrata: An Overall Assessment of in Vitro, Preclinical, Pharmacokinetic and Clinical Data. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Clinical Pharmacokinetics. 2011;50(6):349-69. doi:10.2165/11586800-000000000-00000.
From Bench to Bedside, Boswellic Acids in Anti-Inflammatory Therapy – Mechanistic Insights, Bioavailability Challenges, and Optimization Approaches. Peng C, Yang Y, Wang Y, et al. Frontiers in Pharmacology. 2025;16:1692443. doi:10.3389/fphar.2025.1692443.
Effectiveness of Boswellia and Boswellia Extract for Osteoarthritis Patients: A Systematic Review and Meta-Analysis. Yu G, Xiang W, Zhang T, et al. BMC Complementary Medicine and Therapies. 2020;20(1):225. doi:10.1186/s12906-020-02985-6.
Modulation of the Immune System by Boswellia Serrata Extracts and Boswellic Acids. Ammon HP. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 2010;17(11):862-7. doi:10.1016/j.phymed.2010.03.003.
Deciphering Resveratrol’s Role in Modulating Pathological Pain: From Molecular Mechanisms to Clinical Relevance. Wang B, Jiang HM, Qi LM, et al. Phytotherapy Research : PTR. 2024;38(1):59-73. doi:10.1002/ptr.8021.
Antinociceptive Effect of Resveratrol in Carrageenan-Evoked Hyperalgesia in Rats: Prolonged Effect Related to COX-2 Expression Impairment. Pham-Marcou TA, Beloeil H, Sun X, et al. Pain. 2008;140(2):274-283. doi:10.1016/j.pain.2008.08.010.
Resveratrol Inhibits the Activity of Acid-Sensing Ion Channels in Male Rat Dorsal Root Ganglion Neurons. Wei S, Liu TT, Hu WP, Qiu CY. Journal of Neuroscience Research. 2022;100(9):1755-1764. doi:10.1002/jnr.25060.
Evidence for the Involvement of Opioid and Cannabinoid Systems in the Peripheral Antinociception Mediated by Resveratrol. Oliveira CDC, Castor MGME, Castor CGME, et al. Toxicology and Applied Pharmacology. 2019;369:30-38. doi:10.1016/j.taap.2019.02.004.
Resveratrol-Induced Antinociception Is Involved in Calcium Channels and Calcium/Caffeine-Sensitive Pools. Pan X, Chen J, Wang W, et al. Oncotarget. 2017;8(6):9399-9409. doi:10.18632/oncotarget.14090.
The Dietary Constituent Resveratrol Suppresses Nociceptive Neurotransmission via the NMDA Receptor. Takehana S, Kubota Y, Uotsu N, et al. Molecular Pain. 2017;13:1744806917697010. doi:10.1177/1744806917697010.

Acetyl-L-Carnitine (ALC): Pain Processing Effects vs. Direct Tissue-Modifying Effects

Pain Processing Effects:

ALC exerts analgesia through a unique epigenetic mechanism—it donates acetyl groups to NF-κB p65/RelA, enhancing transcription of the GRM2 gene encoding mGlu2 receptors in the spinal cord dorsal horn.[1][2] This upregulation of mGlu2 receptors at nerve terminals produces analgesia and prevents spinal sensitization. Remarkably, ALC-induced analgesia persists for at least 37 days after drug withdrawal in neuropathic pain models, outlasting pregabalin, amitriptyline, and tramadol, which lose efficacy within 7-15 days post-treatment.[2] ALC also modulates brain neurotransmitters (acetylcholine, serotonin, dopamine) and nerve growth factor (NGF).[1]

Direct Tissue-Modifying Effects:

ALC demonstrates significant nerve regeneration properties. In peripheral nerve injury models, ALC increased myelinated axon counts by 42% compared to controls, improved myelin thickness (0.627 µm vs. 0.408 µm in sham), increased dermal nerve fiber reinnervation by 210%, and reduced muscle atrophy.[3] A systematic review confirmed ALC increases thermal/mechanical tolerance thresholds and reduces apoptosis in sciatic nerve injury models.[4] Notably, ALC also shows chondroprotective effects in osteoarthritis—it decreased MMP-13 expression, partially restored type II collagen levels, and dramatically reduced histopathological scores in a rat OA model.[5]

Mechanism	Pain Processing	Tissue Modification	References
mGlu2 receptor upregulation (epigenetic)	Prevents spinal sensitization; long-lasting analgesia	None	[1], [2]
PKCγ/MAPK activation	Modulates pain signaling	Promotes neuroregeneration	[3]
NGF responsiveness enhancement	Neurotrophic support	Enhances neurite growth	[4]
Mitochondrial support	Reduces oxidative neuronal damage	Promotes axonal transport, myelin synthesis	[5], [6]
MMP-13 inhibition	Indirect (reduces inflammation)	Direct cartilage protection	[7]

References

Acetyl-L-Carnitine in Chronic Pain: A Narrative Review. Sarzi-Puttini P, Giorgi V, Di Lascio S, Fornasari D. Pharmacological Research. 2021;173:105874. doi:10.1016/j.phrs.2021.105874.
Analgesia Induced by the Epigenetic Drug, L-Acetylcarnitine, Outlasts the End of Treatment in Mouse Models of Chronic Inflammatory and Neuropathic Pain. Notartomaso S, Mascio G, Bernabucci M, et al. Molecular Pain. 2017;13:1744806917697009. doi:10.1177/1744806917697009.
Acetyl-L-Carnitine Increases Nerve Regeneration and Target Organ Reinnervation – A Morphological Study. Wilson AD, Hart A, Wiberg M, Terenghi G. Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS. 2010;63(7):1186-95. doi:10.1016/j.bjps.2009.05.039.
The Effect of Acetyl-L-Carnitine (ALCAR) on Peripheral Nerve Regeneration in Animal Models: A Systematic Review. Pourshahidi S, Shamshiri AR, Derakhshan S, Mohammadi S, Ghorbani M. Neurochemical Research. 2023;48(8):2335-2344. doi:10.1007/s11064-023-03911-1.
Prophylactic Role of Acetyl-L-Carnitine on Knee Lesions and Associated Pain in a Rat Model of Osteoarthritis. Bianchi E, Di Cesare Mannelli L, Menicacci C, et al. Life Sciences. 2014;106(1-2):32-9. doi:10.1016/j.lfs.2014.04.022.
The Neuropathy-Protective Agent Acetyl-L-Carnitine Activates Protein Kinase C-Gamma and MAPKs in a Rat Model of Neuropathic Pain. Di Cesare Mannelli L, Ghelardini C, Toscano A, Pacini A, Bartolini A. Neuroscience. 2010;165(4):1345-52. doi:10.1016/j.neuroscience.2009.11.021.
Effects of Acetyl-L-Carnitine in Diabetic Neuropathy and Other Geriatric Disorders. Sergi G, Pizzato S, Piovesan F, et al. Aging Clinical and Experimental Research. 2018;30(2):133-138. doi:10.1007/s40520-017-0770-3.

Summary: Curcumin vs Acetyl-L-Carnitine (ALC) vs Alpha-Lipoic Acid (ALA)

The evidence reveals distinct mechanistic profiles for different nutraceuticals:

Acetyl-L-carnitine (ALC) demonstrates the strongest evidence for epigenetic pain-processing effects with emerging tissue-modifying potential;
Curcumin shows balanced dual effects on both pain pathways and tissue protection; omega-3 fatty acids provide moderate pain-processing benefits with limited structural effects; and
Alpha-lipoic acid (ALA) acts primarily through antioxidant-mediated symptom relief with minimal disease-modifying evidence.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.